Feb 19, 2018 - For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio.I provide an early performance update and
Feb 16, 2018 - Array BioPharma (ARRY) needs investors to pay close attention to the stock based on moves in the options market lately.
Feb 14, 2018 -
Feb 13, 2018 - How to Uncover Institutional Buying
Feb 09, 2018 - For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio.I comment on recent market turmoil and ho
Feb 07, 2018 - The broad U.S. market and the biotech sector rebounded today after hitting a key support level. Will the rebound sustain?Interpreting Array Biopharma's (ARRY) COLUMBUS OS data.Interpeting Allergan's o
Feb 07, 2018 - Stifel issues rating change for ARRY
Feb 07, 2018 - Nabriva has a major catalyst coming up. GW Pharmaceuticals’ marketing application for Epidiolex accepted by EMA. ContraVir announces results from early stage study of Hep B candidate TXL.
Feb 07, 2018 - Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.
Feb 06, 2018 - The combination of better-than-expected quarterly results and upbeat clinical results put traders in a good mood.